Nsouli CRS

Xylitol 7/6/15 12:50 pm    

Xylitol Nasal Irrigation: A Possible Alternative Strategy for the Management of Chronic Rhinosinusitis

Nsouli TM, Diliberto NZ, Nsouli ST, Davis CM, Bellanti JA

Introduction: Chronic rhinosinusitis (CRS), a condition that has been estimated to affect nearly 14% of the population, is associated with significant quality-of-life impairment for the patient and a perplexing therapeutic challenge for the clinician. Although saline irrigation has been shown to be beneficial for patients with rhinosinusitis, xylitol (XLT), a five-carbon sugar alcohol that displays antibacterial properties by enhancing the body’s own innate bactericidal mechanisms, has been suggested as a possible alternative.

Objective: 

The objective of the present pilot study was to evaluate the potential beneficial effect of XLT nasal spray (10% solution) in patients with CRS.

Methods:

This 3-week prospective placebo open-control study evaluated 42 subjects ages 18-53 years with CRS, diagnosed based on published criteria, were randomized to XLT aqueous nasal spray two puffs in each nostril twice daily (n=32) or placebo (n=10). The efficacy of the treatment was assessed by means of evaluating changes from baseline using the sino-nasal outcome test 20 score (SNOT-20) and nasal resistance by using nasal function studies (rhinometry) over a 3-week period.

Results:

All study subjects returned on a weekly basis for 3 weeks and were evaluated using SNOT-20 scores and peak nasal inspiratory flow rates,

using rhinometry (Youlten rhinometer). Utilizing analysis of variance (ANOVA) of study results, after 3 weeks of therapy there was a significant amelioration of the XLT group as compared to the placebo group. The XLT group experienced a reduction of 25.3% in the SNOT-20 scores (p<0.001) and an increase of 35.6% in the nasal inspiratory peak flow (p<0.001) compared to the placebo group.

Conclusion:

XLT aqueous nasal spray resulted in significant improvement of CRS symptoms as compared to placebo and the results of the present study suggest its use as an adjunct therapeutic agent in patients with chronic sinus disease.

Leave a Reply

Your email address will not be published.

*Insurance is designed to pay for the unexpected crisis. Health insurance started that way in the U.S. but gradually, because the companies we work for were paying for it and getting a better tax break, it morphed into paying for it all. That means we have less interest in getting the ounce of prevention than if we were paying for some of those costs. Children we talk to about the dangers of drugs just say they’ll get a brain transplant if they burn theirs out. That’s why we think that Health Savings Accounts should be promoted by the government more; they put the individual back in a position of responsibility in making more choices in their health care. With Health Savings Accounts an ounce of prevention is worth a pound of cure.


Disclaimer: All material provided in this web site is provided for educational purposes in the hope of improving our general health. Access of this web site does not create a doctor-patient relationship nor should the information contained on this web site be considered specific medical advice with respect to a specific patient and/or a specific condition. Copy sections of this page and discuss them with your physician to see if they apply to your own symptoms or medical condition.

Dr. Jones specifically disclaims any liability, loss or risk, personal or otherwise, that is or may be incurred as a consequence, directly or indirectly, of use or application of any of the information provided on this web site.

Copyright © 2014 Common Sense Medicine - Designed By Sebo Marketing